Latest Breaking News On - Debrancher deficiency - Page 1 : comparemela.com

Ultragenyx is a leader in rare diseases, with 4 approved products and 6 pipeline programs. They have $1bn in cash. See why RARE stock is a long-term hold.

Scott stromattMont blancMereo biopharmaGenetx ultragenyxLinked hypophosphatemiaInduced osteomalaciaFamilial hypercholesterolemiaChain fatty acid oxidation disordersDebrancher deficiencyChief medical officerOvid therapeuticsSmall molecule therapiesNeurodevelopmental disorder angelmanEmerging geneNeurodevelopmental disorder angelman syndromeOsteogenesis imperfecta